Use of bismuth subsalicylate in acute diarrhea in children

Humberto E. Soriano-Brücher, Pablo Avendaño, Miguel O’Ryan, Humberto A. Soriano

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Results of a pilot study suggest that bismuth subsalicylate (BSS) favorably altered the course of rotavirus-associated diarrhea in children. This was more evident in those who also had a bacterial pathogen. Subsequently, 123 infants and children with acute diarrhea were admitted to a randomized, parallel, double-blind, placebo-controlled clinical trial. Patients received either BSS at a dosage of 100 mg/(kg.d) for 5 days or a placebo. Patients in the two groups were comparable with respect to age, sex, weight, height, and baseline disease parameters. Compared with subjects treated with placebo, those who received BSS had significantly lower stool weight sooner; improved stool consistency sooner; shorter hospital stay; lower number of stools; decreased need for intravenous fluids; and better evolution of clinical condition. The maximum mean serum level of salicylate occurred on day 3, and the mean blood level of bismuth on the last day of dosing (day 5) was 5.8 ppb.

Original languageEnglish (US)
Pages (from-to)S51-S56
JournalReviews of infectious diseases
Volume12
DOIs
StatePublished - Jan 1 1990

Fingerprint

Diarrhea
Placebos
Weights and Measures
Bismuth
Salicylates
Rotavirus
Controlled Clinical Trials
Length of Stay
Serum
bismuth subsalicylate

Cite this

Use of bismuth subsalicylate in acute diarrhea in children. / Soriano-Brücher, Humberto E.; Avendaño, Pablo; O’Ryan, Miguel; Soriano, Humberto A.

In: Reviews of infectious diseases, Vol. 12, 01.01.1990, p. S51-S56.

Research output: Contribution to journalArticle

Soriano-Brücher, Humberto E. ; Avendaño, Pablo ; O’Ryan, Miguel ; Soriano, Humberto A. / Use of bismuth subsalicylate in acute diarrhea in children. In: Reviews of infectious diseases. 1990 ; Vol. 12. pp. S51-S56.
@article{61a408df3630476d950b60bf1ef3046b,
title = "Use of bismuth subsalicylate in acute diarrhea in children",
abstract = "Results of a pilot study suggest that bismuth subsalicylate (BSS) favorably altered the course of rotavirus-associated diarrhea in children. This was more evident in those who also had a bacterial pathogen. Subsequently, 123 infants and children with acute diarrhea were admitted to a randomized, parallel, double-blind, placebo-controlled clinical trial. Patients received either BSS at a dosage of 100 mg/(kg.d) for 5 days or a placebo. Patients in the two groups were comparable with respect to age, sex, weight, height, and baseline disease parameters. Compared with subjects treated with placebo, those who received BSS had significantly lower stool weight sooner; improved stool consistency sooner; shorter hospital stay; lower number of stools; decreased need for intravenous fluids; and better evolution of clinical condition. The maximum mean serum level of salicylate occurred on day 3, and the mean blood level of bismuth on the last day of dosing (day 5) was 5.8 ppb.",
author = "Soriano-Br{\"u}cher, {Humberto E.} and Pablo Avenda{\~n}o and Miguel O’Ryan and Soriano, {Humberto A.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1093/clinids/12.Supplement_1.S51",
language = "English (US)",
volume = "12",
pages = "S51--S56",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Use of bismuth subsalicylate in acute diarrhea in children

AU - Soriano-Brücher, Humberto E.

AU - Avendaño, Pablo

AU - O’Ryan, Miguel

AU - Soriano, Humberto A.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Results of a pilot study suggest that bismuth subsalicylate (BSS) favorably altered the course of rotavirus-associated diarrhea in children. This was more evident in those who also had a bacterial pathogen. Subsequently, 123 infants and children with acute diarrhea were admitted to a randomized, parallel, double-blind, placebo-controlled clinical trial. Patients received either BSS at a dosage of 100 mg/(kg.d) for 5 days or a placebo. Patients in the two groups were comparable with respect to age, sex, weight, height, and baseline disease parameters. Compared with subjects treated with placebo, those who received BSS had significantly lower stool weight sooner; improved stool consistency sooner; shorter hospital stay; lower number of stools; decreased need for intravenous fluids; and better evolution of clinical condition. The maximum mean serum level of salicylate occurred on day 3, and the mean blood level of bismuth on the last day of dosing (day 5) was 5.8 ppb.

AB - Results of a pilot study suggest that bismuth subsalicylate (BSS) favorably altered the course of rotavirus-associated diarrhea in children. This was more evident in those who also had a bacterial pathogen. Subsequently, 123 infants and children with acute diarrhea were admitted to a randomized, parallel, double-blind, placebo-controlled clinical trial. Patients received either BSS at a dosage of 100 mg/(kg.d) for 5 days or a placebo. Patients in the two groups were comparable with respect to age, sex, weight, height, and baseline disease parameters. Compared with subjects treated with placebo, those who received BSS had significantly lower stool weight sooner; improved stool consistency sooner; shorter hospital stay; lower number of stools; decreased need for intravenous fluids; and better evolution of clinical condition. The maximum mean serum level of salicylate occurred on day 3, and the mean blood level of bismuth on the last day of dosing (day 5) was 5.8 ppb.

UR - http://www.scopus.com/inward/record.url?scp=0025092197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025092197&partnerID=8YFLogxK

U2 - 10.1093/clinids/12.Supplement_1.S51

DO - 10.1093/clinids/12.Supplement_1.S51

M3 - Article

VL - 12

SP - S51-S56

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -